Seizert Capital Partners LLC Acquires 14,465 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Seizert Capital Partners LLC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 59.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,906 shares of the biotechnology company’s stock after purchasing an additional 14,465 shares during the period. Seizert Capital Partners LLC’s holdings in United Therapeutics were worth $13,942,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. USA Financial Formulas acquired a new position in United Therapeutics during the third quarter valued at approximately $33,000. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the second quarter valued at approximately $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the second quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of United Therapeutics during the 3rd quarter worth approximately $82,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on UTHR. TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of United Therapeutics stock in a transaction on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. The trade was a 3.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $44,743.40. The trade was a 96.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,396 shares of company stock valued at $42,175,418. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Down 6.0 %

Shares of NASDAQ:UTHR opened at $363.25 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The business has a 50 day moving average of $362.93 and a 200-day moving average of $328.17. The stock has a market cap of $16.22 billion, a PE ratio of 15.95, a P/E/G ratio of 1.06 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.38 EPS. Equities research analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.